NPC(SH:600713)2018-10-26 16:00Financial Performance - Revenue for the first nine months reached CNY 22.60 billion, a growth of 10.48% year-on-year[6] - Net profit attributable to shareholders increased by 15.41% to CNY 182.19 million for the first nine months[6] - The company reported a basic earnings per share of CNY 0.193, unchanged from the previous year[7] - The company reported a net profit of ¥1,407,858.40 for R&D expenses in Q3 2018, significantly higher than ¥449,789.66 in Q3 2017, showing a growth of 212.5%[38] - The net profit for the third quarter of 2018 was CNY 119.28 million, an increase from CNY 64.03 million in the same period last year, representing an increase of approximately 86.4%[44] - The company reported a total profit of CNY 120.73 million for the third quarter, compared to CNY 66.89 million in the same quarter of the previous year, reflecting a growth of approximately 80.7%[44] - The total comprehensive income for Q3 2018 was ¥51,514,125.44, a decrease from ¥78,549,041.09 in Q3 2017[41] Cash Flow and Financing - The net cash flow from operating activities was negative at CNY -1.24 billion, compared to CNY -1.04 billion in the same period last year[6] - The company raised CNY 8.83 billion through borrowings in the first nine months of 2018, compared to CNY 7.14 billion in the same period last year, indicating a significant increase in financing activities[47] - The total cash inflow from financing activities was CNY 13.36 billion, up from CNY 7.54 billion in the previous year, representing an increase of approximately 77.4%[47] - Net cash flow from operating activities was -¥66,148,206.30, improving from -¥147,012,760.53 year-over-year[50] - Total cash inflow from financing activities amounted to ¥12,663,716,999.46, a significant increase from ¥6,901,000,000.00 in the prior year[52] - Cash and cash equivalents at the end of the period totaled ¥1,109,781,641.88, compared to ¥682,649,930.88 at the end of the previous year[52] Assets and Liabilities - Total assets increased by 21.79% to CNY 19.40 billion compared to the end of the previous year[6] - The company's total liabilities reached CNY 15.14 billion, compared to CNY 12.74 billion at the beginning of the year, representing an increase of about 18.8%[31] - The company's current assets totaled CNY 17.68 billion, up from CNY 14.34 billion at the beginning of the year, indicating a growth of approximately 23.5%[29] - Accounts receivable and notes receivable increased by 36.86% to RMB 11,962,852,022.50 compared to the beginning of the year, mainly due to sales growth and adjustments in sales structure[12] - The company's equity attributable to shareholders rose to CNY 3.83 billion from CNY 2.78 billion, an increase of approximately 37.9%[31] - The total assets of the company as of Q3 2018 amounted to ¥12,215,068,803.35, compared to ¥9,342,949,048.28 at the end of Q3 2017, representing a growth of 30.1%[35] Investments and Acquisitions - The company acquired 51% equity in Suzhou Hengsheng Pharmaceutical Co., Ltd. for a total price of CNY 22.95 million[23] - The company completed the acquisition of 100% equity in Nanjing East China Pharmaceutical Co., Ltd. for CNY 30.51 million and 30% equity in Nanjing Jinling Pharmacy Co., Ltd. for CNY 2.98 million, totaling CNY 33.48 million[24][25] - The company plans to invest CNY 30 million to establish a Traditional Chinese Medicine Cultural Health Industry Center through its subsidiary Nanjing Pharmaceutical Co., Ltd.[25] Research and Development - R&D expenses surged by 307.80% to RMB 4,803,628.45, reflecting the company's increased investment in research and development[13] Shareholder Information - The number of shareholders at the end of the reporting period was 70,344[10] - The largest shareholder, Nanjing Pharmaceutical Group Co., Ltd., holds 23.22% of the shares[10]